3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gynecologic
5
Breast
3
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Lung Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Small Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Liver Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Brain Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
Paclitaxel
12
pembrolizumab
7
Carboplatin
7
Cisplatin
6
Docetaxel
5
sargramostim
4
Taxes
4
Cyclophosphamide
4
Amifostine
4
Trastuzumab
3
Polymerase Chain Reaction
3
Nivolumab
3
Irinotecan
3
Gemcitabine
3
Etoposide
3
talazoparib
2
aldesleukin
2
Vorinostat
2
Vinorelbine
2
SS1(dsFv)PE38
2
Pemetrexed
2
Interleukin-12 Subunit p35
2
Interleukin-12
2
Immunoenzyme Techniques
2
Gene Expression Profiling
2
Flow Cytometry
2
Filgrastim
2
Erlotinib Hydrochloride
2
tocilizumab
1
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Ovarian Epithelial
×
Mass Spectrometry
×
Thoracic
×
Clear all
NCT00900094
2012-02-07
IRB 2000-294
University of Michigan Rogel Cancer Center
Completed
200 enrolled